Gantenerumab does not slow clinical decline in early Alzheimer’s disease
Nov 16, 2023
Two trials show a lower amyloid plaque burden with gantenerumab versus placebo at 116 weeks.
Certain genetic variant in Alzheimer’s disease linked to African ancestry
Feb 22, 2023
An increased risk for Alzheimer’s disease and younger age of onset were seen with the APOE ε3 R145C missense variation.
Georgia to be first state to let pharmacies sell low-dose cannabis
Oct 23, 2023
Meanwhile, the sale of marijuana is still illegal on a federal level
FDA approves new drug to treat Alzheimer’s
Jul 02, 2024
In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
Migraine linked to all-cause dementia, Alzheimer’s disease
Oct 07, 2021
No association was observed between migraine and a risk for vascular dementia in meta-analysis of five cohort studies.
Lilly to seek FDA approval for new drug for Alzheimer’s disease
Jun 25, 2021
Donanemab already has received a ‘breakthrough therapy’ designation from the FDA.
Donepezil tied to risk for overactive bladder
Jan 13, 2022
The risk for overactive bladder varies across individual cholinesterase inhibitor drugs.
Tau PET performs well in predicting dementia in individuals with MCI
Jun 12, 2024
Tau positron emission tomography predicts all-cause dementia and Alzheimer disease dementia
Aortic valve replacement up in patients with Alzheimer’s disease
Sep 17, 2021
One-year outcomes were similar for patients with or without Alzheimer’s disease and related dementias.
Monoclonal antibodies provide small benefits in Alzheimer’s disease
Jan 26, 2024
Harms include increased risks for amyloid-related imaging abnormalities (ARIA)-edema, ARIA-hemorrhage and symptomatic ARIA-edema.